'Clinical follow' diaporamas de présentation

Blood Product Advisory Committee Meeting - July 13, 2006

Blood Product Advisory Committee Meeting - July 13, 2006. Nabi Biopharmaceuticals Hepatitis B Immune Globulin (Human), Intravenous (Nabi-HB IV) Henrik Rasmussen, MD, PhD Senior Vice President Clinical Research, Medical & Regulatory Affairs. Purpose.

633 views • 47 slides

Pathology Journal Reading

Pathology Journal Reading. Presented by Intern ???. Objective. To identify the role of cytokeratins in distinguishing intraductal papilloma from papillary ductal carcinoma in situ. Introduction. Papillary breast tumors: Proliferated mammary epithelium projects into duct lumen

722 views • 33 slides

Dr Dorothy Goddard, Macmillan Associate Medical Director for Cancer

Breast Cancer Pathway: Living with and beyond cancer. Dr Dorothy Goddard, Macmillan Associate Medical Director for Cancer. Risk Stratified Follow Up Recovery Package. What is risk stratified follow up?. Refers to redesign of pathway beyond completion of primary treatment (follow ups)

324 views • 32 slides

Ketil Lunde , Rikshospitalet University Hospital, Oslo, Norway

Intracoronary injection of mononuclear bone marrow cells after acute myocardial infarction Lessons from the ASTAMI trial. Ketil Lunde , Rikshospitalet University Hospital, Oslo, Norway The 4th Symposium on Stem Cell Therapy and Cardiovascular Biology, Madrid, 26 th April 2007.

464 views • 26 slides

ACC/i2 2010 Late-breaking clinical trial session, March 16, 2010

Five year clinical follow-up of the PASSION -trial Five Year Follow-up after Primary PCI with a Pa clitaxel-Eluting S tent versus a Bare-Metal Stent in Acute S T-Elevation Myocardial Infarct ion.

369 views • 25 slides

Emmanouil S. Brilakis , MD, PhD Director, Cardiac Catheterization Laboratory

The SOS ( S tenting O f S aphenous vein grafts) Randomized, Controlled Trial of a Paclitaxel -Eluting Stent Vs. a Similar Bare Metal Stent in Saphenous Vein Graft Lesions. Emmanouil S. Brilakis , MD, PhD Director, Cardiac Catheterization Laboratory VA North Texas Healthcare System

396 views • 24 slides

Safety and Efficacy of Biolimus A9 Eluting Stent with Biodegradable Polymer in Real Life NOBORI 2 Trial: Primary Endpoi

Safety and Efficacy of Biolimus A9 Eluting Stent with Biodegradable Polymer in Real Life NOBORI 2 Trial: Primary Endpoint Data Dr. Gian Battista Danzi. Ospedale Maggiore Policlinico, Milan, Italy. M. Wiemer, R. Koning, A. Serra, K. E. Hauptmann,

382 views • 23 slides

Nothing to disclose

Two-Year Outcomes After Everolimus- or Sirolimus-Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial.

364 views • 23 slides

CREATE Multi-Center Clinical Registry 9-month Angiographic and 12-month Clinical Results

CREATE Multi-Center Clinical Registry 9-month Angiographic and 12-month Clinical Results. Yaling Han MD, FSCAI On behalf of the CREATE investigators March 31, 2008 LBCT of ACC. Presenter Disclosure Information. Name: Yaling Han. NOTHING TO DISCLOSE. CREATE.

236 views • 23 slides

R andomized E arly versus L ate A bci X imab in A cute M yocardial I nfarction treated with primary coronary inter

R andomized E arly versus L ate A bci X imab in A cute M yocardial I nfarction treated with primary coronary intervention (RELAx-AMI Trial). Mauro Maioli M.D., Francesco Bellandi M.D., Mario Leoncini M.D., Anna Toso M.D. and Roberto Piero Dabizzi M.D..

322 views • 20 slides

Follow-up of GI Cancers

306 views • 16 slides

ENDEAVOR II Five-Year Clinical Follow-up

166 views • 16 slides

Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches Herzzentrum Munich Germany

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions . Julinda Mehilli, MD Klinikum der Universitaet Munich Deutsches Herzzentrum Munich Germany . Lecture fees. Abbott Vascular Daichii Sankyo/Lilly

416 views • 15 slides

POST MARKET CLINICAL FOLLOW UP

1.18k views • 15 slides

POST MARKET CLINICAL FOLLOW UP

192 views • 15 slides